Sera Prognostics Q4 2021 Earnings Report
Key Takeaways
Sera Prognostics reported fourth quarter 2021 revenue of $26,000, compared to $6,000 for the same period in 2020. The net loss for the quarter was $12.5 million, compared to $5.4 million for the same quarter a year ago.
Our sales team is focusing geographically in high population density areas, where Anthem and other payers are concentrated.
The recent announcement of the MultiPlan contract is an example of this and we anticipate additional future announcements as we successfully contract with multiple types of payers.
CMS has set a Medicare payment rate of $750 for the existing unique Proprietary Laboratory Analysis (PLA) code, 0247U, for the PreTRM® Test.
Sera was added to the NASDAQ Biotechnology Index® (Nasdaq: NBI) effective Monday, December 20, 2021.